https://pharmadevicenews.com/why-the-boots-group-is-selling-farmacias-benavides-to-farmacias-del-ahorro/ PharmaDeviceNews en 2026-11-14T07:25:10+00:00 Why The Boots Group is selling Farmacias Benavides to Farmacias del Ahorro Comercializadora Farmacéutica de Chiapas, Comisión Nacional Antimonopolio, Farmacias Benavides, Farmacias del Ahorro, Grupo Farmacias del Ahorro, Mexico, Monterrey, Sycamore Partners, The Boots Group https://pharmadevicenews.com/wp-content/uploads/2025/12/pharmadevicenews-1.png https://pharmadevicenews.com/ai-can-design-protein-binders-in-minutes-sino-biological-wants-to-validate-them-in-three-days/ PharmaDeviceNews en 2026-11-14T07:20:51+00:00 AI can design protein binders in minutes. Sino Biological wants to validate them in three days 4RISE, Biacore, Carterra, Houston, Octet, Rob Burgess, Sino Biological, XPressMAX https://pharmadevicenews.com/wp-content/uploads/2025/12/pharmadevicenews-1.png https://pharmadevicenews.com/molecular-designs-has-cleared-its-first-fda-hurdle-can-its-three-virus-pcr-panel-compete-on-workflow/ PharmaDeviceNews en 2026-11-14T07:17:31+00:00 Molecular Designs has cleared its first FDA hurdle. Can its three-virus PCR panel compete on workflow? Alabama, Birmingham, Greer Massey, Michael Clark, Molecular Designs, Simplicity Dx Extraction, SimplicityDx, United States Food and Drug Administration https://pharmadevicenews.com/wp-content/uploads/2026/09/ChatGPT-Image-Sep-14-2026-08_52_17-PM-e1789399378430.webp https://pharmadevicenews.com/dana-farber-cut-cfdna-library-variability-to-8-could-this-solve-a-major-liquid-biopsy-bottleneck/ PharmaDeviceNews en 2026-11-14T07:13:27+00:00 Dana-Farber cut cfDNA library variability to 8%. Could this solve a major liquid biopsy bottleneck? AutoNorm, Dana-Farber Cancer Institute, icon96, iconPCR, Illumina, Integrated DNA Technologies, Molecular Biology Core Facilities, n6 Tec, Twist Bioscience, Zach Herbert https://pharmadevicenews.com/wp-content/uploads/2026/08/0673d3f2-195c-46f3-bb13-83b836d2eb34-e1787420428344.webp https://pharmadevicenews.com/innovent-just-secured-seven-reimbursement-wins-in-china-can-mazdutide-deliver-its-next-growth-surge/ PharmaDeviceNews en 2026-11-14T07:10:30+00:00 Innovent just secured seven reimbursement wins in China. Can mazdutide deliver its next growth surge? China, Daiichi Sankyo, Eli Lilly and Company, Innovent Biologics, Jaypirca, mazdutide, PECONDLE, Picankibart, Sintbilo, TABOSUN, TYVYT, VANFLYTA https://pharmadevicenews.com/wp-content/uploads/2026/09/ChatGPT-Image-Sep-15-2026-09_17_45-AM-e1789444118165.webp https://pharmadevicenews.com/could-routine-ob-gyn-visits-become-a-frontline-defence-against-heart-disease-unified-is-testing-the-idea/ PharmaDeviceNews en 2026-11-14T06:25:58+00:00 Could routine OB/GYN visits become a frontline defence against heart disease? Unified is testing the idea American Heart Association, Elizabeth Cherot, Florida, Go Red for Women Venture Fund, Lucina Analytics, Tampa, Tracy Warren, Unified Women's Healthcare https://pharmadevicenews.com/wp-content/uploads/2026/09/ChatGPT-Image-Sep-13-2026-10_25_46-AM-e1789275382436.webp https://pharmadevicenews.com/imfinzis-new-bladder-cancer-regimen-cut-death-risk-by-42-can-astrazeneca-win-against-an-approved-rival/ PharmaDeviceNews en 2026-11-14T06:22:13+00:00 IMFINZI’s new bladder cancer regimen cut death risk by 42%. Can AstraZeneca win against an approved rival? Astellas Pharma, AstraZeneca, durvalumab, enfortumab vedotin, Imfinzi, Keytruda, Merck & Co., PADCEV, Pfizer, United States Food and Drug Administration, VOLGA https://pharmadevicenews.com/wp-content/uploads/2026/08/PDN-tablets-generic-e1788149113473.webp https://pharmadevicenews.com/zai-lab-just-secured-reimbursement-for-two-growth-medicines-can-2027-reverse-its-revenue-decline/ PharmaDeviceNews en 2026-11-14T06:18:29+00:00 Zai Lab just secured reimbursement for two growth medicines. Can 2027 reverse its revenue decline? argenx, AUGTYRO, Bristol Myers Squibb, China, KarXT, National Healthcare Security Administration, NUZYRA, QINLOCK, Vyvgart Hytrulo, Zai Lab https://pharmadevicenews.com/wp-content/uploads/2026/08/Schizophrenia-research-e1786477838518.webp https://pharmadevicenews.com/ionis-reports-95-fewer-hae-attacks-after-two-years-can-dawnzera-defend-its-dosing-advantage/ PharmaDeviceNews en 2026-11-14T06:15:20+00:00 Ionis reports 95% fewer HAE attacks after two years. Can DAWNZERA defend its dosing advantage? American College of Allergy Asthma and Immunology, Dawnzera, donidalorsen, Ionis Pharmaceuticals, OASIS-HAE, OASISplus, United States Food and Drug Administration https://pharmadevicenews.com/wp-content/uploads/2026/08/Therapy-for-hereditary-angioedema-e1787681209572.webp https://pharmadevicenews.com/drug-testing-has-been-stuck-with-paper-for-decades-did-i3collect-just-change-the-rules/ PharmaDeviceNews en 2026-11-14T06:11:41+00:00 Drug testing has been stuck with paper for decades. Did i3collect just change the rules? Desert Tox, i3collect, National Laboratory Certification Program, Premier Biotech, Substance Abuse and Mental Health Services Administration, United States Department of Transportation https://pharmadevicenews.com/wp-content/uploads/2025/12/pharmadevicenews-1.png https://pharmadevicenews.com/clene-cut-a-six-week-als-data-task-to-one-week-can-faster-analysis-help-its-9-9m-cash-runway/ PharmaDeviceNews en 2026-11-14T04:01:22+00:00 Clene cut a six-week ALS data task to one week. Can faster analysis help its $9.9m cash runway? Clene Inc., Clene Nanomedicine, CNM-Au8, HEALEY ALS Platform Trial, InStat, RESCUE-ALS, RESTORE-ALS, United States Food and Drug Administration, Veristat https://pharmadevicenews.com/wp-content/uploads/2026/01/neurological-basis-of-amyotrophic-lateral-sclerosis.webp https://pharmadevicenews.com/evidation-captured-1300-symptom-assessments-in-60-days-could-blood-sampling-finally-reveal-what-happens-during-autoimmune-flares/ PharmaDeviceNews en 2026-11-14T03:58:05+00:00 Evidation captured 1,300 symptom assessments in 60 days. Could blood sampling finally reveal what happens during autoimmune flares? Evidation, Leslie Oley Wilberforce, London Life Sciences Week, PACE, Precision in Autoimmune Condition Evidence, San Mateo, Sunny Khan https://pharmadevicenews.com/wp-content/uploads/2026/08/PDN-Diagnostics-2-generic.webp https://pharmadevicenews.com/i2pure-says-conventional-iodine-strength-can-conceal-a-delivery-problem-what-does-the-chemistry-reveal/ PharmaDeviceNews en 2026-11-14T03:54:19+00:00 I2Pure says conventional iodine strength can conceal a delivery problem. What does the chemistry reveal? ACS Omega, American Chemical Society, Christopher Moses, I2Pure Corporation, Ilker Bayer, Jack Kessler, Maggie Engert https://pharmadevicenews.com/wp-content/uploads/2025/12/pharmadevicenews-1.png https://pharmadevicenews.com/rocket-pharmaceuticals-has-an-approved-gene-therapy-and-279m-in-cash-can-it-deliver-on-both-fronts/ PharmaDeviceNews en 2026-11-14T03:51:41+00:00 Rocket Pharmaceuticals has an approved gene therapy and $279m in cash. Can it deliver on both fronts? European Medicines Agency, Hercules Capital, KRESLADI, Rocket Pharmaceuticals, RP-A501, RP-A601, RP-A701, United States Food and Drug Administration https://pharmadevicenews.com/wp-content/uploads/2026/04/biotech-research-technology-for-chronic-myeloid-leukemia-drug-development-e1777170361532.webp https://pharmadevicenews.com/celanese-just-sold-another-19-of-nutrinova-for-152m-why-is-mitsui-taking-greater-control/ PharmaDeviceNews en 2026-11-14T03:48:04+00:00 Celanese just sold another 19% of Nutrinova for $152m. Why is Mitsui taking greater control? Celanese Corporation, Dallas, Frankfurt, Germany, Mitsui & Co., Nutrinova Netherlands, Sunett https://pharmadevicenews.com/wp-content/uploads/2025/12/pharmadevicenews-1.png https://pharmadevicenews.com/organons-vtama-achieved-up-to-70-easi75-response-in-one-eczema-subgroup-how-broadly-do-the-results-apply/ PharmaDeviceNews en 2026-11-13T08:14:06+00:00 Organon’s VTAMA achieved up to 70% EASI75 response in one eczema subgroup. How broadly do the results apply? ADORING 1, ADORING 2, ADORING 3, American College of Allergy Asthma and Immunology, Dermavant Sciences, Organon, Sun Pharmaceutical Industries, tapinarof, VTAMA https://pharmadevicenews.com/wp-content/uploads/2026/01/severe-atopic-dermatitis-symptoms.webp https://pharmadevicenews.com/kalvistas-oral-hae-drug-is-approved-now-five-studies-are-testing-what-treatment-changes-in-real-life/ PharmaDeviceNews en 2026-11-13T08:11:08+00:00 KalVista’s oral HAE drug is approved. Now five studies are testing what treatment changes in real life American College of Allergy Asthma and Immunology, Chiesi Global Rare Diseases, Chiesi Group, EARLY, EKTERLY, KalVista Pharmaceuticals, KONFIDENT, KONFIDENT-S, sebetralstat https://pharmadevicenews.com/wp-content/uploads/2025/12/pharmadevicenews-1.png https://pharmadevicenews.com/volta-labs-cuts-axelios-1-library-prep-hands-on-time-to-one-hour-can-laboratories-scale-faster/ PharmaDeviceNews en 2026-11-13T08:08:17+00:00 Volta Labs cuts AXELIOS 1 library prep hands-on time to one hour. Can laboratories scale faster? Association for Molecular Pathology, AXELIOS 1, Callisto, Genome in a Bottle, Roche, Roche Diagnostics, SBX-D, Volta Labs https://pharmadevicenews.com/wp-content/uploads/2026/08/PDN-Diagnostics-generic.webp https://pharmadevicenews.com/mitotech-is-testing-a-different-way-to-burn-fat-could-mt-1101-complement-glp-1-drugs/ PharmaDeviceNews en 2026-11-13T08:05:06+00:00 Mitotech is testing a different way to burn fat. Could MT-1101 complement GLP-1 drugs? Anton Petrov, Mitotech, MT-1101, Natalia Perekhvatova, ObesityWeek, semaglutide, The Obesity Society https://pharmadevicenews.com/wp-content/uploads/2026/09/Oral-metabolic-drug-research-e1790707052160.webp https://pharmadevicenews.com/cambrian-bios-atx-304-raised-resting-metabolic-rate-by-up-to-33-could-obesity-treatment-move-beyond-appetite-suppression/ PharmaDeviceNews en 2026-11-13T08:01:51+00:00 Cambrian Bio’s ATX-304 raised resting metabolic rate by up to 33%. Could obesity treatment move beyond appetite suppression? American Diabetes Association, ATX-304, Cambrian Bio, Cambrian BioPharma, ObesityWeek, REWIRE-1, REWIRE-2, The Obesity Society https://pharmadevicenews.com/wp-content/uploads/2026/04/Khondrion-begins-pivotal-sonlicromanol-study-in-m.3243AG-disease-with-a-sharper-regulatory-strategy-e1776657813549.webp https://pharmadevicenews.com/lineage-buys-a-huntingtons-disease-cell-therapy-with-six-patients-treated-can-hunt1-overcome-the-next-hurdle/ PharmaDeviceNews en 2026-11-13T03:58:39+00:00 Lineage buys a Huntington’s disease cell therapy with six patients treated. Can HUNT1 overcome the next hurdle? Brian Culley, California Institute for Regenerative Medicine, hNSC-01, HUNT1, Leslie Thompson, Lineage Cell Therapeutics, NeuroAirmid Therapeutics, REGEN4HD, University of California Irvine https://pharmadevicenews.com/wp-content/uploads/2026/07/Huntingtons-disease-drug-research-e1783863352980.webp https://pharmadevicenews.com/ardent-health-is-buying-a-480m-revenue-hospital-system-for-47m-whats-behind-the-deal/ PharmaDeviceNews en 2026-11-13T03:55:43+00:00 Ardent Health is buying a $480m revenue hospital system for $47m. What’s behind the deal? Ardent Health, Boone Health, Boone Health Medical Group, Boone Hospital Center, Columbia, Dave Caspers, Missouri https://pharmadevicenews.com/wp-content/uploads/2025/12/pharmadevicenews-1.png https://pharmadevicenews.com/diamedica-has-reached-200-stroke-trial-patients-could-its-next-two-readouts-change-dm199s-future/ PharmaDeviceNews en 2026-11-13T03:52:08+00:00 DiaMedica has reached 200 stroke trial patients. Could its next two readouts change DM199’s future? DiaMedica Therapeutics, DM199, Health Canada, ReMEDy2, Tygerberg Hospital, United States Food and Drug Administration https://pharmadevicenews.com/wp-content/uploads/2026/08/PDN-Clinical-Trials.webp https://pharmadevicenews.com/what-veradermics-latest-oral-minoxidil-data-reveal-about-long-term-hair-growth/ PharmaDeviceNews en 2026-11-13T03:48:39+00:00 What Veradermics’ latest oral minoxidil data reveal about long-term hair growth Jefferies, Study 302, Study 304, Study 306, United States Food and Drug Administration, VDPHL01, Veradermics https://pharmadevicenews.com/wp-content/uploads/2026/07/VDPHL01-female-hair-loss-data-to-test-Veradermics-extended-release-minoxidil-strategy-e1784095007570.webp https://pharmadevicenews.com/aptar-pharma-just-removed-a-critical-development-barrier-for-complex-nasal-drugs-how-much-could-change/ PharmaDeviceNews en 2026-11-13T03:45:29+00:00 Aptar Pharma gains DEA registration for controlled-substance nasal and inhaled drug development Aptar Pharma, AptarGroup, Boonton, New Jersey, United States Drug Enforcement Administration https://pharmadevicenews.com/wp-content/uploads/2026/05/Aptar-Pharma-advances-FDA-backed-research-into-next-generation-metered-dose-inhalers-e1778298889267.webp